Assessment of rhenium-186 obisbemeda (186RNL) therapy for recurrent glioblastoma (rGBM) using MRI and SPECT imaging biomarkers (SNO 2025) - Dec 2, 2025 - Abstract #IMG-94; Pres time: Nov 22, 2025; 11:45 AM - 01:05 PM; Location: Hawaii Convention Center, Kamehameha Exhibit Hall II & III; "These findings support the effectiveness of combining MRI and SPECT imaging to access 186RNL delivery and its therapeutic outcomes in rGBM. Imaging biomarkers such as TCR, MTT and TTP may serve as useful predictors of treatment response and clinical outcomes and could guide future patient-specific treatment planning."
Biomarker • Brain Cancer • Glioblastoma • Solid Tumor
|
|
Shiliang Huang; Michael Youssef; Toral Patel; Michael Schulder; Pierre Giglio; Joel Michalek; Ande Bao; William Philips; Melissa Moore; John Floyd; William Kelly; Andrew Branner
|